本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600594 证券简称：益佰制药 公告编号：2025-040 贵州益佰制药股份有限公司 关于年度审计机构变更签字注册会计师的公告 肖缨不存在违反《中国注册会计师职业道德守则》对独立性要求的情形， 最近三年未受（收）到任何刑事处罚、行政处罚、行政监管措施和自律监管措 施,具备相应专业能力和丰富的从业经验。 三、本次变更对公司的影响 贵州益佰制药股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开了第八届董事会第十一次会议，于 2025 年 5 月 16 日召开了 2024 年年度股东 大会，审议通过了《关于续聘公司 2025 年年度审计机构的议案》，同意续聘中 证天通会计师事务所（特殊普通合伙）（以下简称"中证天通"）为公司 2025 年年度财务报告及内部控制审计机构，具体内容详见公司于 2025 年 4 月 26 日 在上海证券交易所网站（www.sse.com.cn）披露的《贵州益佰制药股份有限公 司关于续聘公司 2025 年年度审计机构的公告》（ ...

Investment Rating - The report does not explicitly provide an investment rating for the gynecological drug industry in China. Core Insights - The biopharmaceutical industry in China is experiencing structural optimization, valuation recovery, and confidence rebuilding, particularly in the Hong Kong market, where the 18A system supports enterprise value discovery [2][3]. - Gynecological drug companies are characterized by specialized positioning and differentiated competition, focusing on areas such as traditional Chinese medicine, innovative treatments for gynecological tumors, and hormone drugs, showcasing strong professional images and commercialization capabilities [2][3]. Summary by Sections Capital Market Performance of China's Biopharmaceutical Sector - The A-share market has shifted from a focus on scale to sustainable development, while the Hong Kong market has attracted international capital through the 18A system, leading to a gradual rebuilding of long-term confidence in the biopharmaceutical sector [3][25]. - The A-share biopharmaceutical sector has seen a total fundraising amount of 787 billion yuan from January to October 2025, with a peak of 2,451 billion yuan in 2021, indicating a transition from a capital overheating phase to a rational development phase [13][18]. - In the Hong Kong market, the total fundraising amount reached 789 billion HKD from January to October 2025, with a peak of 1,833 billion HKD in 2020, reflecting a significant improvement in the financing environment [27][28]. Market Position Assessment of Chinese Gynecological Drug Companies - The competitive landscape of gynecological drug companies is marked by a focus on specialized fields such as innovative gynecological tumor drugs and hormone treatments, with companies establishing differentiated competitive advantages [40]. - Qianjin Pharmaceutical is recognized as a leading player in the gynecological drug market, with a strong market presence in oral gynecological inflammation traditional Chinese medicine [40]. - Heng Rui Pharmaceutical is noted for its robust pipeline in gynecological tumor treatments, with eight drugs in development as of 2024 [40]. - Xianju Pharmaceutical specializes in hormone treatments, with a focus on steroid drugs, establishing a strong professional image in the gynecological field [40]. Introduction to Representative Listed Chinese Gynecological Drug Companies - Qianjin Pharmaceutical has a significant market share of 25.8% in oral gynecological inflammation traditional Chinese medicine, demonstrating strong sales performance even in challenging market conditions [45]. - Heng Rui Pharmaceutical's research and development pipeline includes multiple innovative treatments for gynecological tumors, indicating a solid commitment to this therapeutic area [52][53]. - Xianju Pharmaceutical leverages its expertise in steroid drugs to maintain a competitive edge in the gynecological drug market, with a focus on cost-effective production and high-quality formulations [58][61].

Group 1 - The National Healthcare Security Administration of China released a court criminal judgment excerpt regarding a bribery case involving Liu Mouhong, the director of the pharmacy department at Shuangshan Hospital in Anshan City [1] - Liu Mouhong utilized his position to assist others in drug procurement and increasing procurement volume [1] - The case is linked to Guizhou Yibai Pharmaceutical Co., Ltd., where a salesperson was involved in ensuring the supply of a specific product while excluding competitors [3] Group 2 - The judgment revealed that Liu Mouhong accepted a total of 6,000 yuan from a salesperson to facilitate the procurement of Yibai Pharmaceutical's Ginkgo Biloba injection [3] - The bribery occurred in September 2015 and January 2016, just before the Spring Festival [3] - The case highlights issues of corruption within the pharmaceutical procurement process in Chinese hospitals [3]

Core Viewpoint - The announcement details the pledge and release of shares by the controlling shareholder of Guizhou Yibai Pharmaceutical Co., Ltd., indicating a total of 21,000,000 shares pledged, which represents 11.32% of the shareholder's holdings and 2.65% of the company's total shares [2][7]. Share Pledge Situation - Controlling shareholder Dou Qiling holds 185,457,636 shares, accounting for 23.42% of the company's total shares [2]. - The total number of pledged shares by Dou Qiling and her concerted action person Dou Yaqi is 21,000,000 shares, which is 11.31% of their combined holdings and 2.65% of the company's total shares [2]. Release of Pledged Shares - The announcement confirms that the pledged shares are not used for major asset restructuring performance compensation or other guarantees [3]. - The company will disclose any future use of the released shares for other pledge activities [5]. Shareholder Pledge Summary - As of the announcement date, the total pledged shares by the controlling shareholder and concerted action persons are detailed, with a note on rounding differences in data [6]. Future Pledge Outlook - Dou Qiling has no shares maturing in the next six months, and the total shares maturing within the next year (excluding those maturing in six months) is 21,000,000 shares, which is 11.32% of her total holdings and 2.65% of the company's total shares [7]. - Dou Qiling's credit status is good, and she has the financial capability to repay, with funds sourced from her own and self-raised funds [8]. - There are no risks of forced liquidation, and the pledge and release of shares will not affect the company's operations or governance, nor will it lead to a change in actual control [8].

重要内容提示: 控股股东窦啟玲女士持有贵州益佰制药股份有限公司（以下简称"公司"） 股份数量 185,457,636 股，占公司总股本的 23.42%，控股股东窦啟玲女士持有 公司股份累计质押数量（含本次质押和解除质押）为 21,000,000 股，占其持股 数量的 11.32%，占公司总股本的 2.65%。 控股股东窦啟玲女士及其一致行动人窦雅琪女士累计质押股份数量（含本 次质押和解除质押）为 21,000,000 股，占窦啟玲女士及其一致行动人窦雅琪女 士合计所持公司股份的 11.31%，占公司总股本的 2.65%。 证券代码：600594 证券简称：益佰制药 公告编号：2025-039 贵州益佰制药股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，公司获悉控股股东窦啟玲女士将所持有的本公司部分股份办理了股 票质押及解除质押业务，具体情况如下： 注：以上数据因四舍五入原因导致数据在尾数上略有差异。 被质押股份不存在被用作重大资产重组业绩补偿等事项的担保或其他保障 ...

Core Viewpoint - The announcement from Yibai Pharmaceutical indicates that the controlling shareholder, Dou Qiling, has engaged in partial share pledges and releases, which are primarily aimed at debt repayment and do not pose a risk to the company's operations or control [1] Group 1: Share Pledge Details - Dou Qiling pledged 21 million shares to Guotai Junan Securities, representing 11.32% of her holdings and 2.65% of the total share capital, for debt repayment, starting from November 26, 2025, and maturing on November 26, 2026 [1] - On November 27, 2025, Dou Qiling will release 22.6683 million shares from pledge, which accounts for 12.22% of her holdings and 2.86% of the total share capital [1] - The total pledged shares by Dou Qiling and her concerted parties amount to 21 million shares, representing 11.31% of their combined holdings and 2.65% of the total share capital [1] Group 2: Risk Assessment - The company assesses that the risk associated with the pledged shares is manageable and will not affect its operations or control [1]

Group 1 - The board of directors of Guizhou Yibai Pharmaceutical Co., Ltd. held its 15th meeting of the 8th session on November 26, 2025, to address urgent matters, waiving the notice period as per company regulations [2][5] - All 7 directors attended the meeting, which was chaired by Chairwoman Dou Qiling [3][4] - The meeting was compliant with the Company Law and the company's articles of association [5] Group 2 - The board approved the proposal to supplement the independent director position, following the resignation of independent director Chen Yisong due to personal reasons [6] - Liang Liang was elected as the new independent director and will also serve as the chair of the audit committee, a member of the nomination committee, and a member of the remuneration and assessment committee [6] - Liang Liang holds a PhD in management from Tohoku University, Japan, and is currently an associate professor at Guizhou University, with no prior shareholding in the company [8]

每经头条（nbdtoutiao）——国开行辟谣的"人民资产"是什么？记者实探：号称投资600元80天赚8万 元！一位投资人的女儿：劝不住她，警察都拦不住 2024年1至12月份，益佰制药的营业收入构成为：医药工业占比77.44%，医疗收入占比21.46%，其他业 务占比1.1%。 截至发稿，益佰制药市值为33亿元。 每经AI快讯，益佰制药（SH 600594，收盘价：4.23元）11月26日晚间发布公告称，公司第八届第十五 次董事会临时会议于2025年11月26日在公司行政楼会议室以现场加通讯会议方式召开。会议审议了《关 于增补公司第八届董事会专门委员会委员的议案》等文件。 （记者 胡玲） ...

北京市君致律师事务所 关于贵州益佰制药股份有限公司 2025 年第二次临时股东会 法 律 意 见 书 北京 · 东城区北三环东路 36 号环球贸易中心 B 座 11 层 100013 电话（Te1）: 010-52213236/52213237/52213238/52213239 ्Ӣᐸੑ㠪ᗁᐾӁࣗᡶ ީӄ䍫ᐔⴀ֦㦥㛗Գᴿ䲆ޢਮ ᵜ㿱Җᡰᴹᮠ٬؍⮉єսሿᮠˈ㤕ࠪ⧠ᙫᮠо࠶亩ᮠ٬ѻ઼нㅖⲴᛵ ഐᡰ㠤DŽޕѪഋ㠽ӄˈ൷ߥ ᵜᡰᖻᐸṩᦞޣ⌅ᖻǃ⌅㿴઼㿴㤳ᙗ᮷ԦⲴ㾱≲ˈ᤹➗ᖻᐸ㹼ъޜ䇔Ⲵ ъ࣑ḷ߶ǃ䚃ᗧ㿴㤳઼औࣹቭ䍓㋮⾎ˈࠪާ⌅ᖻ㿱ྲл˖ жȽᵢ⅗㛗ђՐⲺਢ䳼Ƚਢᔶぁᓅ ˄а˅㓿ᵜᡰᖻᐸṨḕˈޜਨҾ ᒤ ᴸ ᰕਜᔰⲴㅜޛቺ㪓һՊㅜ 1 ᒪㅢӂ⅗Ѫᰬ㛗ђՐ ⌋ᗁᝅ㿷Ҝ 㠪φ䍫ᐔⴀ֦㦥㛗Գᴿ䲆ޢਮ ेӜᐲੋ㠤ᖻᐸһ࣑ᡰ˄ԕлㆰ〠Āᵜᡰā˅᧕ਇ䍥ᐎ⳺֠ࡦ㦟㛑ԭᴹ䲀ޜ ਨԕлㆰ〠Ā⳺֠ࡦ㦟āᡆĀޜਨā Ⲵငᢈˈᤷ⍮ᖻᐸࠪᑝ⳺֠ࡦ㦟 ᒤ ㅜҼ⅑Ѥᰦ㛑ьՊ˄ԕлㆰ〠Āᵜ⅑㛑ьՊā˅DŽṩᦞljѝॾӪ≁ޡ઼ഭ䇱ࡨ⌅NJ ԕлㆰ〠Ālj䇱ࡨ⌅NJā ǃljѝॾӪ≁ޡ઼ഭޜਨ⌅NJԕлㆰ〠Āljޜਨ⌅NJā ઼ljкᐲޜਨ㛑ьՊ㿴ࡉN ...

证券代码：600594 证券简称：益佰制药 公告编号：2025-037 贵州益佰制药股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 26 日 (二)股东会召开的地点：贵州益佰制药股份有限公司行政楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，董事长窦啟玲女士主持，会议采用现场投票 与网络投票相结合的方式进行表决，本次会议的召集、召开和表决方式符合《公 司法》及《公司章程》的有关规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事7人，列席7人； 2、公司董事会秘书出席会议；公司其他高管列席会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：《关于增补公司独立董事的议案》 审议结果：通过 表决情况： | 1、出席会议 ...